Status:

UNKNOWN

Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients

Lead Sponsor:

Sun Yat-sen University

Conditions:

Nasopharyngeal Carcinoma

Eligibility:

All Genders

18-70 years

Brief Summary

NPC Patients receiving IMRT treatment will receive a dedicated FDG PET/CT and high-sensitivity PET/CT protocol simultaneously in the follow-up of Locally Advanced Nasopharyngeal Carcinoma. Hence we es...

Detailed Description

Newly-diagnosed patients with stage III or IV non-metastatic Nasopharyngeal Carcinoma (AJCC 8th) will be recruited. All subjects receiving chemoradiotherapy will undergo a baseline integrated \[18F\]f...

Eligibility Criteria

Inclusion

  • Patients must be informed of the investigational nature of this study and given written informed consent.
  • Aged between 18-70, male/female.
  • Staged III or IV (AJCC 8th) NPC patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma (including differentiated type and undifferentiated type, WHO II and III).
  • Received induction chemotherapy and/or concurrent chemoradiotherapy. ECOG scale 0-1.
  • Fertile women should practice contraception during the study period.
  • HGB ≥90g/L ,WBC ≥4\*109/L , PLT ≥100\*109/L,
  • With normal liver function test (ALT and AST ≤2.5\*ULN, TBil ≤2.0\*ULN)
  • With normal renal function test (serum creatinine ≤1.5\*ULN)

Exclusion

  • Women in pregnancy or lactation
  • Prior malignancy except adequately treated basal cell, squamous cell skin cancer, or cervical cancer in situ.
  • Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), and emotional disturbance.
  • Already involved in other clinical trial.
  • Mental disorder, civil disability, limited capacity for civil conduct.

Key Trial Info

Start Date :

May 20 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 20 2020

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT04394091

Start Date

May 20 2020

End Date

December 20 2020

Last Update

May 19 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China, 510060